Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States

Key Points Question Is atezolizumab plus bevacizumab, carboplatin, and paclitaxel (atezolizumab combination) cost-effective as a first-line treatment strategy for US patients with metastatic nonsquamous non–small cell lung cancer? Findings In this economic evaluation of 1 million simulated patients with metastatic nonsquamous non–small cell lung cancer, adding atezolizumab to bevacizumab, carboplatin, and paclitaxel was not cost-effective at a willingness-to-pay threshold of $100 000 per quality-adjusted life-year, compared with bevacizumab, carboplatin, and paclitaxel alone. Atezolizumab combination also provided suboptimal incremental benefit compared with cost vs pembrolizumab combination for first-line treatment. Meaning Although atezolizumab combination therapy provides clinical benefit, price reductions may be necessary for this treatment strategy to become cost-effective.